AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00720759
Drug: Placebo + distributed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
Trial: NCT02146664
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Trial: NCT02146664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Trial: NCT03944031
Drug: LY3372689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00437762
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection
Trial: NCT00688064
Drug: Vehicle Gel associated with Doxycycline Hyclate
RxNorm normalized name: doxycycline hyclate Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Trial: NCT01706328
Drug: FF/VI 100/25 Inhalation Powder NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
Trial: NCT01706328
Drug: Placebo Inhalation Powder NDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
Trial: NCT01706328
Drug: Placebo Inhalation Powder ACCUHALER/DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
Trial: NCT04468711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus topical 1% hydrocortisone cream twice daily
Trial: NCT00787761
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume).
Trial: NCT01138072
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg once daily
Trial: NCT00787761
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push.
Trial: NCT02162316
Drug: Motilitone®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02162316
Drug: A-Cilin®, Clari® and Pantoline®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04326829
Drug: QL1604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1604, IV infusion
Trial: NCT01138072
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Simvastatin single dose
Trial: NCT01138072
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg rosuvastatin single dose
Trial: NCT03325114
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
Trial: NCT03797664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate Buffer Diluent oral solution
Trial: NCT01346085
Drug: CNI free immunosuppression
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
Trial: NCT00118105
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
Trial: NCT02767232
Drug: Standard Anticoagulation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation determined by physician for a period of 3-6 months
Trial: NCT00055978
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally. 400mg twice daily for 6 months.
Trial: NCT00417690
Drug: PASER placebo granules
RxNorm normalized name: Paser D/R Granule Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
Trial: NCT00331890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As active drug
Trial: NCT04484337
Drug: Topical non-steroidal anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug will be available for topical application
Trial: NCT04484337
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid will be available for topical application
Trial: NCT04484337
Drug: Placebo creams/gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo creams/gels will be available for topical application
Trial: NCT00622609
Drug: GSK249320A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
Trial: NCT00622609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride intravenous infusion will be given as matching placebo.
Trial: NCT00337571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily, 8 weeks
Trial: NCT03856970
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 μg tablets for oral administration
Trial: NCT02386033
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Trial: NCT02296073
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
Trial: NCT00092807
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03023787
Drug: Hepalatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Trial: NCT03023787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Trial: NCT03353220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is made to mimic Belviq, but does not contain any active drug
Trial: NCT02279953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04670679
Drug: ERAS-601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01531205
Drug: Androgen Ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
Trial: NCT01531205
Drug: Salvage Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
Trial: NCT00959751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg capsules with no active ingredient designed to match the NXN-188 capsules
Trial: NCT03218501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is to be administered orally once daily for 2 weeks
Trial: NCT00498550
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remain on pre-study antipsychotic treatment
Trial: NCT03861039
Drug: Oral antihyperglycemic medication (OAM)
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
Trial: NCT01089647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
Trial: NCT02060006
Drug: Meloxicam 7.5mg daily for 8 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5mg daily for 8 weeks
Trial: NCT01566370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01168141
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg ZD4054 daily in tablet form
Trial: NCT00332280
Drug: AMT2003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic dosage, take once when limosis in the morning.
Trial: NCT02212067
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Trial: NCT03392298
Drug: Colla corii asini
RxNorm normalized name: CORID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15g Colla corii asini granule, once daily for 4 weeks
Trial: NCT00586625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop, both eyes, twice a day
Trial: NCT00551447
Drug: MK0733, simvastatin / Duration of Treatment: 27 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00551447
Drug: Comparator: simvastatin / Duration of Treatment: 27 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02021773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Trial: NCT00870727
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical in size and appearance to study drug.
Trial: NCT00720278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg Placebo daily
Trial: NCT01712516
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Trial: NCT01712516
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT01712516
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT01712516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Trial: NCT01675609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye daily for up to 35 days
Trial: NCT00737048
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen two oral capsules will be administered once as 650 mg.
Trial: NCT00737048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
Trial: NCT00737048
Drug: Tramadol plus Acetaminophen
RxNorm normalized name: acetaminophen / tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
Trial: NCT00090532
Drug: AG-013,958
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04576000
Drug: Janus Kinase Inhibitor
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
Trial: NCT01196507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
Trial: NCT01870284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00219609
Drug: UK-390,957
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01345019
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Trial: NCT01345019
Drug: Placebo to zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Trial: NCT02864758
Drug: Vitamin K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, dose is based on International Normalized Ratio
Trial: NCT01375322
Drug: Valsartan+Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
Trial: NCT00136201
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00950807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive/ excipients only
Trial: NCT00950807
Drug: GSK573179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573179 investigational drug
Trial: NCT04276883
Drug: Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Film for BXCL501
Trial: NCT01434121
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
Trial: NCT01434121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741871
Drug: SB1518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
Trial: NCT04534283
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
Trial: NCT01041781
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01243996
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
Trial: NCT01648764
Drug: LY2334737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01464138
Drug: Fosmidomycin and Clindamycin co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
Trial: NCT00980876
Drug: Ciprofloxacin HCl and Hydrocortisone
RxNorm normalized name: ciprofloxacin / hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin Hydrochloride and Hydrocortisone
Trial: NCT03979313
Drug: MEDI8897
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RSV monoclonal antibody with an extended half-life
Trial: NCT03979313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% (w/v) saline
Trial: NCT02056678
Drug: acetaminophen, IV preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00330070
Drug: IPL512,602 20 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00330070
Drug: IPL512,602 Matching Placebo once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999868
Drug: UST Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
Trial: NCT01999868
Drug: ABA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
Trial: NCT00574639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
Trial: NCT02560467
Drug: Echo and myocardial contrast echocardiography perfusion imaging
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses.
Trial: NCT01694134
Drug: Hydrocortancyl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an intradiscal injection of hydrocortancyl.
Trial: NCT00634504
Drug: glucarpidase, high-dose methotrexate, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous dose
Trial: NCT00634504
Drug: high-dose methotrexate, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care, leucovorin every 6 hours
Trial: NCT00676143
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Trial: NCT01513499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Placebo single-dose administration